Diagnostic Kits/Patents limit medical potential of sequencing: Difference between revisions
Jump to navigation
Jump to search
AClearwater (talk | contribs) No edit summary |
AClearwater (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
Merz, J.F., 2002. Patents limit medical potential of sequencing. Nature, 419(6910), 878. | |||
*Merz, J.F., 2002 - This brief comment by Merz makes two important points. Quick and easy gene sequences will be limited because of patents and licensing. First, some patent holders will not license their patents which will prevent a comprehensive test form being developed. Second, given those that do license the amount of licenses required and the stacked royalty payments will make the test prohibitively expensive. | *Merz, J.F., 2002 - This brief comment by Merz makes two important points. Quick and easy gene sequences will be limited because of patents and licensing. First, some patent holders will not license their patents which will prevent a comprehensive test form being developed. Second, given those that do license the amount of licenses required and the stacked royalty payments will make the test prohibitively expensive. | ||
Latest revision as of 16:31, 10 September 2009
Merz, J.F., 2002. Patents limit medical potential of sequencing. Nature, 419(6910), 878.
- Merz, J.F., 2002 - This brief comment by Merz makes two important points. Quick and easy gene sequences will be limited because of patents and licensing. First, some patent holders will not license their patents which will prevent a comprehensive test form being developed. Second, given those that do license the amount of licenses required and the stacked royalty payments will make the test prohibitively expensive.